Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.61 |
| ▸ | GABRD | O14764 | 2/20 | 0.61 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.61 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.61 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.61 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.61 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.61 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.61 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.61 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.61 |
| ▸ | GABRE | P78334 | 2/20 | 0.61 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.61 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.61 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.61 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.61 |
| ▸ | LDHA | P00338 | 1/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15547132 | 0.86 | GABRP (0.44) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL18068216 | 0.84 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30964013 | 0.84 | GABRP (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30414922 | 0.84 | KCNQ3 (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL15713423 | 0.84 | KCNQ3 (0.43) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL30096979 | 0.82 | NNMT (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL22291660 | 0.82 | NNMT (0.59) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29773884 | 0.81 | NAPRT (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL979398 | 0.81 | NAPRT (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL16441418 | 0.79 | ALDH1A1 (0.41) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4096651-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2026-05-27 | — | — | EP | disclosed |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2026-03-19 | — | — | US | disclosed |
| US-12391686-B2 | Compounds and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-08-19 | — | — | US | disclosed |
| EP-4590674-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | Sironax Ltd (KY) | 2025-07-30 | — | — | EP | disclosed |
| WO-2025137158-A1 | DERIVATIVES OF ([1,2,4]TRIAZOLO[5,1-A]ISOQUINOLINE-5-CARBONYL)GLYCINATE AS PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250085300-A1 | STABILITY-ENHANCING COMPOSITIONS AND METHODS OF PREPARING COMPOUNDS | FOGHORN THERAPEUTICS INC. | 2025-03-13 | — | — | US | disclosed |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-20240325370-A1 | THERAPEUTIC REGIMENS OF A DEGRADER OF BRD9 | FOGHORN THERAPEUTICS INC. | 2024-10-03 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186743-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2007-03-06 | — | — | US | disclosed |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | BERGMANIS ARIJA A | 2005-11-17 | — | — | US | disclosed |
| US-6956052-B2 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORATION (US) | 2005-10-18 | — | — | US | disclosed |
| EP-1501805-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| EP-1444207-A2 | SUBSTITUTED PYRAZOLYL-COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | Pharmacia Corporation (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | PHARMACIA CORPORARTION | 2004-06-10 | — | — | US | disclosed |
| WO-2003095430-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-11-20 | — | — | WO | disclosed |
| WO-2003024935-A2 | SUBSTITUTED PYRAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250085300-A1 | STABILITY-ENHANCING COMPOSITIONS AND METHODS OF PREPARING COMPOUNDS | GCDH, GLRX3, GRHPR | GABRP 513/4885GABRD 447/4885GABRA1 560/4885 |
| US-20260078130-A1 | NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF | NAMPT, NNMT, SARM1 | GABRP 1598/4885GABRD 2635/4885GABRA1 2625/4885 |
| US-20040110741-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | GABRP 4263/4885GABRD 4299/4885GABRA1 4273/4885 |
| US-12391686-B2 | Compounds and uses thereof | VHL, TFEB, BECN1 | GABRP 1829/4885GABRD 3060/4885GABRA1 1289/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | GABRP 2224/4885GABRD 2810/4885GABRA1 2494/4885 |
| US-20240325370-A1 | THERAPEUTIC REGIMENS OF A DEGRADER OF BRD9 | BRD9, SND1, SBDS | GABRP 1695/4885GABRD 266/4885GABRA1 1264/4885 |
| US-20050256180-A1 | Substituted pyrazolyl compounds for the treatment of inflammation | IRAK4, IL1B, IRAK2 | GABRP 4263/4885GABRD 4299/4885GABRA1 4273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.